JAKPOT T1D  

This trial will test two drugs, called abrocitinib and ritlecitanib. The trial will test whether these drugs can allow people newly diagnosed with type 1 diabetes (T1D) to keep producing their own insulin for longer. These two drugs are part of a drug family called ‘JAK inhibitors’.